A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)

Trial Profile

A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2018

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept
  • Sponsors Syntimmune
  • Most Recent Events

    • 17 May 2018 Preliminary data from this trial was presented at the International Investigative Dermatology conference, According to a Syntimmune media release.
    • 17 May 2018 Results from Cohort 1 (n=7) presented in the Syntimmune media release.
    • 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top